About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702·12 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Biogen

With

Elan Pharmaceuticals

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

For arms 1,2,3 and 4: Diagnosis of Secondary Progressive Multiple Sclerosis (SPMS)
For arms 5 and 6: Diagnosis of relapsing forms of Multiple Sclerosis (MS).
No past history of receiving natalizumab.

You may not be if

For arms 1,2,3 and 4 Diagnosis of primary progressive MS or relapsing-remitting MS.
Form arms 5 and 6: Diagnosis of primary progressive MS or secondary progressive MS without the occurrence of relapses.

The record

StatusCompleted

PhasePhase 1

Taking part76

StartedOct 2007

UpdatedSep 9, 2014

Conditions

Relapsing-Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Where12

Research Site
Phoenix, Arizona, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Berkeley, California, United States